Navigation Links
Bionomics Achieves US$1 Million Milestone Payment from Genmab
Date:2/19/2008

s for cancer to the clinic."

The CEO of Genmab Lisa N Drakeman, PhD commented: "We are pleased to reach the next level of development with these targets and look forward to continuing the collaboration with Bionomics."

Professor Jan G J van de Winkel, PhD, Chief Scientific Officer of Genmab added: "This milestone has been reached following extensive studies by Genmab on the Bionomics targets. The work we have undertaken has confirmed and extended the work performed by Bionomics, further supporting their potential as new targets for therapeutic antibodies."

Bionomics has the rights and is actively developing a large number of additional proprietary proteins discovered through its angiogenesis program, including BNO69. In addition Bionomics' anti-cancer drug BNC105 will soon commence a Phase 1 clinical trial at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Western Hospital cancer centres in Melbourne for the treatment of solid tumours including breast, colon and prostate cancers. BNC105 was identified using the Angene(R) platform. Bionomics' Investigational New Drug (IND) submission for BNC105 was accepted by the US Food and Drug Administration in November 2007.

About Bionomics Limited:

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' discovery and development activities are driven by its three technology platforms: Angene(R), the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore(R) is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX(R) is a set of novel technologies for the identification of drugs targeting ion channels for diseases of t
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... Medical Systems, a global developer of high-end ultrasound systems, ... number of clinical applications and ranked first or second ... KLAS  "Ultrasound 2011: Innovation on the Move" report. ... monitoring and reporting the performance of information technology and ...
... Suneva Medical, a privately-held aesthetic medical device ... aesthetics injectable business with approval from Health Canada ... dermal filler for nasolabial folds or smile line ... long-lasting treatment, Bellafill provides physicians the opportunity to ...
Cached Medicine Technology:ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 2ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 3Suneva Medical Announces Canadian Approval of Bellafill™ 2
(Date:9/18/2014)... drink less sugar, according to a new study from ... enough, the study goes on to say, as all ... healthier at school , The research suggests a parent,s ... a child,s diet. , The study found Vancouver school ... per cent more likely to eat vegetables during the ...
(Date:9/18/2014)... 18, 2014 Relias Learning, the leader in ... services markets, today announced it has been named to the ... companies in America. , In the three-year period from 2010 ... almost 2,000 spots on the Inc. 5000 list to 1,025 ... , “The industries we serve continue to grow, and the ...
(Date:9/18/2014)... Gables, FL (PRWEB) September 18, 2014 ... a portion of proceeds to Feeding America Eastern Wisconsin. ... Days, 7 Ways to Save” with Turbana bananas and ... be two for $4 and Turbana bananas will be ... $1 for every two Fyffes pineapples that are purchased ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical Center ... EV™ for physicians — improving productivity ... solutions, Holyoke chose T-System’s solution because not only ... reimbursement, but also its ability to integrate with ... to capture emergency department, (ED) nurse documentation. , ...
(Date:9/18/2014)... Fit Body Boot Camp , an ... in the country and its popularity, as both a franchise ... enormously in 2014. , The company’s annual business conference, ... in Costa Mesa, CA on September 26 and 27, and ... Founder Bedros Keuilian, who is also considered the leading fitness ...
Breaking Medicine News(10 mins):Health News:Kids eat better if their parents went to college 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 3Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... arteries remains the leading cause of disease and death in ... Medicine researcher is helping to open new pathways toward treating ... of biomedical sciences, is researching mutant forms of a human ... grow new blood vessels to restore blood flow in damaged ...
... Source Endurance is pleased to,announce that it ... Sports and,Fitness of San Marcos Texas to collaborate ... encompass several areas of,collaboration including the sharing and ... training approaches, and deployment of one,of the first ...
... Children,s Research Hospital have demonstrated that children with ... can retain normal function in both kidneys by ... when preoperative scans suggest that the tumors are ... St. Jude patients with bilateral Wilms tumor exhibiting ...
... Programs to be Marketed to Over 50,000 Members ... ... CANTEL MEDICAL,CORP. (NYSE: CMN ) and the National Safety Council ... prepare for the threat of a flu pandemic and similar,infectious diseases. The ...
... A SpaCapsule, Could Change The Outcome Of This ... Year,s Presidential Election, MIAMI, March 24 ... John McCain, Hillary Clinton and,Barack Obama,s stress levels are at an all ... city to city making,numerous public appearances. This can cause lack of sleep ...
... A study by a New York University dental research ... (gum) disease are more likely to develop gestational diabetes ... , The study, led by Dr. Ananda P. Dasanayake, ... NYU College of Dentistry, followed 256 women at New ...
Cached Medicine News:Health News:FSU researcher's 'mutant' proteins could lead to new treatment for heart disease 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 3Health News:St. Jude study offers new hope for children with kidney tumors deemed inoperable 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 3Health News:Stress On The Campaign Trail, One Issue All The Candidates Agree On 2Health News:NYU dental researchers find evidence of periodontal disease leading to gestational diabetes 2
Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
Delicate strong curved serrated tips. Serrated handle with dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
Medicine Products: